Mastocytomas, also known as a Mast Cell Tumors (MCT) are the most common neoplasm in dogs and account for 16 to 21% of all skin tumors. MCT’s may appear as warty-like nodules, a soft lump or an ulcerated skin mass. These tumors are often aggressive, metastasizing to the lymph nodes, spleen, bone marrow and liver. To diagnose a MCT a veterinarian should perform a fine needle aspiration on all lumps and if identified as a MCT a surgical biopsy should be performed to determine the grade of the tumor. The tumors grading starts at a Grade 1, meaning a low potential for metastasis (reoccurrence) and progresses up to a Grade 3, highly aggressive metastasis.
Surgery is the option of choice whenever possible for MCT’s. If the tumor is not resectable or a Grade 2 or higher is given after a surgical biopsy, Kinavet CA1 would be an option. Kinavet CA1 is a new cutting-edge technology that makes it possible to target the cells responsible for the advancement and growth of these aggressive tumors. Mastinib, the active ingredient in Kinavet CA1, is a tyrosine kinase inhibitor able to target the origin of cancer. Kinavet CA1 is the first drug registered in the treatment of cancer in Veterinary Medicine and clinical development programs have also been implemented for the use of Kinavet CA1 in melanoma, T cell lymphoma, haemangiosarcome, histiocytoma, osteosarcoma as well as inflammatory diseases such as canine atopic dermatitis, canine arthritis, canine inflammatory bowel disease and feline asthma.
Kinavet CA1 is a once a day tablet administered by mouth and the most common side effects include lethargy, vomiting, diarrhea and decreased appetite. Patients treated with Kinavet CA1 will need to be seen by their veterinarian every two weeks for blood tests to check for other possible side effects. Kinavet CA1 is metabolized in the liver and has not been evaluated in dogs under two years old and cannot be used in dogs weighing less than 15 pounds. AB Science conducted the clinical trial and 2 year follow-up study. In 50% of the study population treated with Kinavet CA1 the tumor size decreased by half or more during the first 6 months of treatment. For more information visit www.Kinavet.com or contact your veterinarian.
Kinavet CA1 is an anti-cancer drug so it is vital that extra care be given when handling this drug, administering the drug to your dog and cleaning up after your dog.
· Children should not come in contact with Kinavet CA1 or feces, urine or vomit of treated dogs.
· You may not handle Kinavet CA1 if you are pregnant, nursing or may become pregnant.
· Wash hands immediately after handling Kinavet CA1.
· Do not split or break tablets to avoid disrupting the protective coating
· Administer immediately after removing from bottle
· Gloves should be worn if handling broken tablets as well as tablets that become moistened.
· If your dog spits a tablet out you must wear gloves to handle the tablet
· If the tablet is hidden in food you must make sure the entire tablet was ingested
· Gloves must be worn when cleaning any feces, urine or vomit of dogs taking Kinavet CA1
· You must not wash any items soiled with urine, feces or vomit with other laundry.
· Disposal of feces, urine, vomit or disposable towels must be in a sealed plastic bag to minimize the potential of exposure.
By Sarah Zumhofe
Surgery is the option of choice whenever possible for MCT’s. If the tumor is not resectable or a Grade 2 or higher is given after a surgical biopsy, Kinavet CA1 would be an option. Kinavet CA1 is a new cutting-edge technology that makes it possible to target the cells responsible for the advancement and growth of these aggressive tumors. Mastinib, the active ingredient in Kinavet CA1, is a tyrosine kinase inhibitor able to target the origin of cancer. Kinavet CA1 is the first drug registered in the treatment of cancer in Veterinary Medicine and clinical development programs have also been implemented for the use of Kinavet CA1 in melanoma, T cell lymphoma, haemangiosarcome, histiocytoma, osteosarcoma as well as inflammatory diseases such as canine atopic dermatitis, canine arthritis, canine inflammatory bowel disease and feline asthma.
Kinavet CA1 is a once a day tablet administered by mouth and the most common side effects include lethargy, vomiting, diarrhea and decreased appetite. Patients treated with Kinavet CA1 will need to be seen by their veterinarian every two weeks for blood tests to check for other possible side effects. Kinavet CA1 is metabolized in the liver and has not been evaluated in dogs under two years old and cannot be used in dogs weighing less than 15 pounds. AB Science conducted the clinical trial and 2 year follow-up study. In 50% of the study population treated with Kinavet CA1 the tumor size decreased by half or more during the first 6 months of treatment. For more information visit www.Kinavet.com or contact your veterinarian.
Kinavet CA1 is an anti-cancer drug so it is vital that extra care be given when handling this drug, administering the drug to your dog and cleaning up after your dog.
· Children should not come in contact with Kinavet CA1 or feces, urine or vomit of treated dogs.
· You may not handle Kinavet CA1 if you are pregnant, nursing or may become pregnant.
· Wash hands immediately after handling Kinavet CA1.
· Do not split or break tablets to avoid disrupting the protective coating
· Administer immediately after removing from bottle
· Gloves should be worn if handling broken tablets as well as tablets that become moistened.
· If your dog spits a tablet out you must wear gloves to handle the tablet
· If the tablet is hidden in food you must make sure the entire tablet was ingested
· Gloves must be worn when cleaning any feces, urine or vomit of dogs taking Kinavet CA1
· You must not wash any items soiled with urine, feces or vomit with other laundry.
· Disposal of feces, urine, vomit or disposable towels must be in a sealed plastic bag to minimize the potential of exposure.
By Sarah Zumhofe
RSS Feed
